Wearable-delivered Parkinson’s therapy shows promise in early trial
An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics' long-acting form of apomorphine, advance to a second dosing group.
Useful takeaways from this story.
An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics' long-acting form of apomorphine, advance to a second dosing group.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics' long-acting form of apomorphine, advance to a second dosing group.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.